Cellectis S.A. (CLLS) stock
CLLSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.03−0.03 (-2.83%)
Close on Nov 18, 2026Market cap $103.35MP/E –Yield –
Cellectis revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
For fiscal 2025 it was $72.95M, up 75.8% from the year before. Over ten years it grew 2.7% a year on average. The highest annual figure on record is $72.95M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $72.95M | +75.8% |
| FY2024 | Dec 31, 2024 | $41.51M | +5397.4% |
| FY2023 | Dec 31, 2023 | $755.00K | -96.1% |
| FY2022 | Dec 31, 2022 | $19.17M | -36.8% |
| FY2021 | Dec 31, 2021 | $30.35M | -40.6% |
| FY2020 | Dec 31, 2020 | $51.06M | +236.1% |
| FY2019 | Dec 31, 2019 | $15.19M | +19.3% |
| FY2018 | Dec 31, 2018 | $12.73M | -49.5% |
| FY2017 | Dec 31, 2017 | $25.19M | -43.8% |
| FY2016 | Dec 31, 2016 | $44.81M | -19.8% |
| FY2015 | Dec 31, 2015 | $55.86M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $5.23M | +300.1% |
| Q2 FY2025 | Jun 30, 2025 | $16.73M | +49.7% |
| Q2 FY2024 | Jun 30, 2024 | $8.06M | +178.0% |
| Q2 FY2023 | Jun 30, 2023 | $178.00K | -84.5% |
| Q2 FY2022 | Jun 30, 2022 | $1.31M | – |
| Q2 FY2021 | Jun 30, 2021 | $11.18M | – |
| Q2 FY2020 | Jun 30, 2020 | $2.90M | – |
| Q2 FY2019 | Jun 30, 2019 | $1.15M | – |
See a number that looks wrong?